Navigation Links
Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
Date:9/5/2013

PALO ALTO, Calif., Sept. 5, 2013 /PRNewswire/ -- Signature Therapeutics, Inc., today presented four scientific posters at the PAINWeek 2013 national conference in Las Vegas.  The posters illustrate the company's (i) trypsin-labile, immediate- and extended-release opioid prodrugs that release the parent opioid following oral administration; (ii) results of extended-release prodrugs oxycodone and hydromorphone withstanding tampering and abuse using standard crushing and extracting techniques; and (iii) First-in-man study findings of its trypsin-liable extended-release hydromorphone prodrug.

(Logo:  http://photos.prnewswire.com/prnh/20130729/SF54809LOGO)

Every year in the United States prescription opioid abuse is responsible for tens of thousands of deaths and tens of billions of dollars in increased health care costs.  Wes Sterman, President and CEO of Signature Therapeutics, commented, "We believe that our prodrug technology approach creating abuse-deterrent opioid drugs has the potential to greatly impact the public health crisis of prescription drug abuse."

About The Opioid Abuse Challenge

The abuse and misuse of prescription opioid drugs has reached epidemic proportions in the United States. Despite efforts to develop opioid drug formulations that are resistant to tampering, abusers will soon match the advances in pill/tablet formulation technology with new ways to abuse these drugs.  Typical methods of abuse of prescription opioid drugs include inhaling or injecting crushed pills or chewing intact pills.  Current efforts to thwart these modes of abuse, involving improved tablet-formulation technology to make tablets harder to crush and the opioid drug harder to remove from the tablet, provide some increased level of abuse-resistance.  However, Signature Therapeutics' prodrug technology involves creating new molecules that provide very high levels of abuse-resistance based upon the design of the molecules themselves.

About Signature Therapeutics

Signature Therapeutics, Inc. is a development-stage biopharmaceutical company located in Palo Alto, California.  The Company focuses on the discovery and development of a portfolio of novel chemical entities for the potential treatment of neurological disorders.

Signature Therapeutics Contact:

Carey DeRafael

email: cderafael@signaturerx.com
phone: 650-331-4006
website: http://www.signaturerx.com



'/>"/>
SOURCE Signature Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Senator Shares Insight on Florida Physician Dispensing Legislation as First Guest of Progressive Medicals New SignatureSeries
2. Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
3. CLAAD Lauds Signature Therapeutics R&D Efforts To Reduce Prescription Drug Abuse
4. Wacoms New DTU-1031 Provides Paperless Electronic Signature Solution for Businesses
5. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
6. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
7. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
8. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
10. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
11. Autoinjectors to 2018 - Devices, Therapeutics, Markets, Strategies and Prospects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... 8, 2017  StatLab Medical Products ("StatLab" ... manufacturer of diagnostic supplies for the anatomic ... & Company LP ("Cressey & Company"), a ... growth-focused investment in the Company. Cressey & ... from selling shareholder, Prairie Capital, L.P., with ...
(Date:6/5/2017)... , June 5, 2017 The ... brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded ... Cincinnati Enquirer . Results are based on an ... in organizational health and workplace improvement. The survey measures several ... ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
Breaking Medicine Technology:
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... ... Male Fertility & Sexual Medicine Specialists, in collaboration with the Fertility Center of ... male fertility care: PESA (percutaneous epidydimal sperm aspiration) and TESA (percutaneous testicular sperm ...
(Date:6/26/2017)... , ... June 26, 2017 , ... ... to a recent review of government data released by the United Soybean Board. ... management practices, Maryland’s soybean farmers have increased their productivity on less land per ...
(Date:6/26/2017)... CA (PRWEB) , ... June 26, 2017 , ... ... qualified mental health professionals in every state across the country to join its online ... and rewarding way for therapists to reach a substantially greater number of people in ...
(Date:6/26/2017)... ... June 26, 2017 , ... KICKICO , a ... that pledges to solve many catastrophic issues within funding campaigns. KICKICO developers are ... typical notion of crowdfunding - the raising of funds through the power of many ...
(Date:6/25/2017)... (PRWEB) , ... June 25, 2017 , ... FCPX LUT ... into an old-fashioned vintage look. FCPX LUT Vintage Volume 2 contains 60 different color-grade ... grain for distorted looks, vignettes and blurs to single out subjects, plus much more. ...
Breaking Medicine News(10 mins):